Research Article

Identification of a Functional Type IA Topoisomerase, *Ld*TopIIIβ, from Kinetoplastid Parasite *Leishmania donovani*

Bijoylaxmi Banerjee,[1] Nilkantha Sen,[2] and Hemanta K. Majumder[1]

[1] *Molecular Parasitology Laboratory, Infectious Disease and Immunology Division, Indian Institute of Chemical Biology, 4, Raja S. C. Mullick Road, Kolkata 700032, India*
[2] *Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA*

Correspondence should be addressed to Hemanta K. Majumder, hkmajumder@iicb.res.in

DNA topoisomerases of kinetoplastids represent a family of DNA processing enzymes that essentially solve the topological problems not only in nuclear DNA but also in kinetoplast DNA. We have, for the first time, identified a *Leishmania donovani* homologue of bacterial and eukaryotic IA type of topoisomerase III protein and termed as *Ld*TopIIIβ. Complementation study of wild-type and mutant *Ld*TopIIIβ with slow-growing topoisomerase III mutant yeast *S. cerevisiae* revealed the functional conservation of the leishmanial counterpart of topoisomerase IIIβ protein, the 327 tyrosine being the active site amino acid. A C-terminal deletion construct of *Ld*TopIIIβ could not suppress the slow-growth phenotype of mutant yeast, indicating the requirement of C-terminal region for the enzyme function *in vivo*. *Ld*TopIIIβ localized inside the nucleus and kinetoplast of the parasite. Taken together, our study indicates functional conservation and possible role of *Ld*TopIIIβ in parasite DNA processing.

1. Introduction

DNA topoisomerases are ubiquitous enzymes found in all prokaryotic and eukaryotic cells and in some viruses. They are involved in all aspects of DNA metabolism such as replication, transcription, recombination, and chromosome segregation [1, 2]. These reactions are based on sequential breakage and rejoining of the DNA phosphodiester backbone [2–4]. Type I DNA topoisomerases catalyze the cleavage of one strand of DNA, whereas type II DNA topoisomerases catalyze the cleavage of a double-stranded DNA, requiring ATP as a cofactor [4].

Type I DNA topoisomerases are further classified in two subfamilies, IA and IB, based on differences in amino acid sequence and reaction mechanisms [5]. The type IA enzymes link covalently to cleaved DNA through the 5′-phosphate. They are represented by bacterial topoisomerase I and III and the eukaryotic topoisomerase III enzymes. Type IB topoisomerases, exemplified by eukaryotic topoisomerase I, in contrast, become attached to 3′-phosphate end of the cleaved strand of the DNA [4]. Type IA topoisomerases are highly conserved from bacteria to humans.

While the function of topoisomerase II and I are quite well established, the role of topoisomerase III in DNA metabolism is still being defined. Genes encoding topoisomerase III enzymes are highly conserved in evolution from bacteria to human, and the phenotypic consequences of loss of topoisomerase III function are generally quite severe. It has been shown to possess a weak, ATP-independent relaxation activity towards negatively supercoiled DNA only and strict dependence on magnesium [6].

The *E. coli* chromosome encodes two type IA topoisomerase, DNA topoisomerase I [7] and topoisomerase III [8, 9]. Loss of topoisomerase III in *E. coli* results in an increase in deletions arising from recombination events between direct repeats [10, 11]. Yeast cells express a single type IA topoisomerase, topoisomerase III encoded by the *Top3* gene. In *S. pombe*, *top3* is essential for viability and plays a role in chromosome segregation [12]. It has been shown that *top3*-ts mutant *S. pombe* cells are sensitive to the DNA damaging agents UV and MMS (methyl methanesulfonate) at the restrictive temperature revealing that topoisomerase III is involved in DNA damage survival [13]. In *S. cerevisiae*, *top3*Δ mutants are viable, but very slow-growing and have

defects in S phase responses to DNA damage and in both mitotic and meiotic recombination [14, 15]. In vertebrates, there are two isoforms of topoisomerase III enzymes termed α and β [16–19]. Deletion of mouse topoisomerase IIIα gene led to embryonic lethality [20]. Deletion of mouse topoisomerase IIIβ gene displayed shortened lifespan and infertility [21, 22].

DNA topoisomerases of kinetoplastids represent a family of DNA processing enzymes that essentially solve the topological problems not only in the nuclear DNA but also in the kinetoplastid DNA. The IB type of bi-subunit topoisomerase I and topoisomerase II of the parasites which maintain vital cellular processes, are also proven target for clinically useful antitumor drugs [23]. Apart from this IB type of topoisomerase I, three type IA topoisomerases are there in the parasite genome, termed as topoisomerase IA, and two topoisomerase III. Topoisomerase IA of *T. brucei* has been reported and shown to be mitochondrial and essential for late theta structure resolution [24]. Very recently, a Topoisomerase IIIα from *T. brucei* has been shown to play a critical role in antigenic switching [25]. In the present study, for the first time, we have identified functionally active DNA topoisomerase IIIβ from kinetoplastid parasite *L. donovani*, which localized both inside the nucleus and kinetoplast of the parasite and rescued the topoisomerase III mutant yeast from slow-growth phenotype.

2. Materials and Methods

2.1. Parasite Culture and Maintenance. *L. donovani* strain AG 83 promastigotes were grown at 22°C in M199 liquid media supplemented 10% heat inactivated fetal calf serum. Transfected cells were maintained under the same conditions with 100 μg/mL G418.

2.2. Strains, Media, and Growth Conditions. The *Escherichia coli* strains used were DH5α and BL21 (DE3) pLysS. If required, ampicillin and chloramphenicol were used at 100 and 34 μg/mL final concentrations, respectively. The yeast strains used in the studies were W5909-3B (MAT alpha trp1-1 his3-11, 15 leu2-3, 112 ura3-1 RAD5 LYS2 MET15 ADE2) and W2633-4C (a/alpha top3:: TRP1/+) (kindly gifted by Dr. R Rothstein). The yeast cells were grown at 25°C on YEPD medium containing 1% peptone, 2% yeast extract, 2% dextrose and 1.5% agar or synthetic minimal media as required.

2.3. Cloning of Topoisomerase IIIβ Gene from Leishmania donovani. *LdTopIIIβ* gene was PCR amplified from the genomic DNA of *L. donovani* parasites using the sense primer 5′-GGAAATTCCATATGGGCCGCA ATGTGTTGATG-3′ and antisense primer 5′-CGGGATCCTCACCTGCGATC-CTCGCGGTTGCC-3′ and was cloned in bacterial expression vector pET16b in *Nde*1 and *Bam*H1 restriction sites, termed as *LdTopIIIβ-pET16b*.

2.4. Structural Analysis and Homology Modeling. Multiple sequence alignment of *Ld*TopIIIβ sequences from various species was carried out using CLUSTAL W (http://expasy .org/tools). Three-dimensional models of *Ld*TopIIIβ based on the crystal structure of *E. coli* topoisomerase III were generated using Swiss Prot (http://expasy.org/sprot). The generated files were opened in RasMol (http://www.rasmol.org/). The protein sequences were represented in ribbon format and the active site residues were represented in ball and stick format over the ribbon structure.

2.5. Construction of Expression Vectors and Transfection in Leishmania. *LdTOPIIIβ* genes was PCR amplified using *LdTopIIIβ-pET16b* as templates and was subcloned using the sense primer 5′-CGGGATCCATGGGCCGCA ATG-TGTTGATG-3′ and antisense primer 5′-GATATCCCTGCG-ATCCTCGCGGTTGCC-3′ in *Bam*H1 and *Eco*RV sites of *Leishmania* transfection vector pXG-B2863 (a kind gift from Dr. S. M. Beverley), to produce C-terminal-GFP-tagged full-length *Ld*TopIIIβ protein and termed as *LdTopIIIβ*-GFP. The constructs and empty vector pXG-B2863 were transfected into *L. donovani* promastigotes separately by electroporation as described earlier [26]. Briefly, late log-phase promastigotes were harvested and washed twice in OPTI-MEM (GIBCO). Cells were finally suspended at a density of 1×10^8/mL and 0.4 mL was taken into a 0.2 mm ice-chilled electroporation cuvette. Thirty microgram of plasmid DNA was taken in 100 μL of electroporation buffer and added to the cells. After 10 min on ice, the cells were electroporated with a single pulse by Bio-Rad Gene Pulsar apparatus using 450 V and 550 μF capacitance. The cells were incubated on ice for further 5 min and then added to 10 mL of drug-free growth medium. After 24 h of survival 10 μg/mL G418 was added and kept at 22°C. The transfected cells were monitored visually by microscope and drug concentration was increased gradually. Finally the transfected cells were routinely maintained in medium containing 100 μg/mL G418.

2.6. Fluorescence Microscopy. Localization of C-terminal GFP tagged chimeric *Ld*TopIIIβ-GFP protein was visualized by fluorescence microscopy (Olympus IX81). Cell nucleus and kinetoplast were stained with DAPI. Differential visualization of the fluophores was achieved using a 488 nm excitation filters and 523 nm emission filter for GFP and 258 nm excitation and 361 nm emission filter for DAPI.

2.7. Construction of Mutants. The full-length *LdTopIIIβ* was subcloned in *Xba*I and *Bam*H1 sites into the yeast shuttle vector pVT100U, a kind gift from Dr. Rolf Sternglanz [27] and termed as *LdTopIIIβ-pVT* using the sense primer 5′-GCTCTAGAATGGGCCGCAATGTGTTGATG-3′ and antisense primer 5′-CGGGATCCTCACCTGCGATCCTC-GCGGTT-3′. For construction of C-terminal deletion construct of *LdTopIIIβ*, regions corresponding to amino acids 1-608 was PCR amplified using the primers 5′-GCTCTAGAATGGGCCGCAATGTGTTGATG-3′ (sense) and 5′-CGGGATCCGGCGGCGGAGATGGCGGAGAA-3′ (antisense) and was cloned in *Xba*1 and *Bam*H1 sites of pVT100U vector.

2.8. Site-Directed Mutagenesis. Single mutations were introduced in *LdTOPIIIβ* at position Tyr 327 (Y327). Mutagenesis was performed by using the QuikChangeXL site-directed kit (Stratagene, La Jolla, CA) according to the manufacturer's protocol. To carry out the desired mutations, *LdTopIIIβ-pVT* was used as templates for all mutagenesis experiments. For each mutation, the wild-type nucleotide was replaced using a specific pair of mutagenic primers. The following sense primer, along with the antisense counterparts (with codons in boldface and substitutions underlined), were used; for Y327 of *LdTopIIIβ*, sense primer was 5′-CCGCGGCTA-TATTTCG**TTC**CCTCGTACCCGAATCC-3′ and antisense primer was 5′-GGATTCGGTACGAGG**GAA**CGAAATATA-GCCGCGG-3′.

2.9. Complementation Assay. The *top3* mutant yeast strain W2633-4C (a/alpha top3:: TRP1/+) (a kind gift from Dr. R Rothstein) was used for transformation with recombinant topo III proteins from *L. donovani* by the lithium acetate and polyethylene glycol method [28]. The transformants were cultured on solid synthetic minimal medium at 30°C for 2 days. Colonies were picked and cultured in tubes with 2 mL of synthetic minimal media at 30°C overnight.

2.10. Expression of Recombinant LdTopIIIβ Using the Express-way Cell-Free E. coli Expression System (Invitrogen). In vitro transcription and translation of *Ld*TopIIIβ proteins were carried out according to the manufacturer's protocol. *LdTopIIIβ-pET16b* plasmids were used as DNA templates for synthesis of the protein. After the reaction is over, the crude bacterial lysate containing the newly synthesized protein was tested for activity.

2.11. DNA Relaxation Activity by LdTopIIIβ. The type IA DNA topoisomerases were assayed by decreased mobility of the relaxed isomers of supercoiled pBS (SK+) [pBluescript (SK+)] DNA in an agarose gel. Relaxation assay was carried out with the crude lysates containing the *in vitro* transcribed and translated *Ld*TopIIIβ. Supercoiled pBS DNA (85%–95% were negatively supercoiled with the remaining being nicked circles) was used as substrate in the relaxation buffer (25 mM Tris-HCl, pH 7.5, 5% glycerol, 0.5 mM DTT, 2 mM $MgCl_2$, 50 μg/mL BSA). The amount of supercoiled monomer DNA band fluorescence after EtBr (0.5 μg/mL) staining was visualized using Gel Doc 2000 under UV illumination (Bio-Rad Quality one Software).

3. Results

3.1. Type IA Topoisomerase Genes in Leishmania. A search of the *Leishmania major* genome database yielded three type IA topoisomerases. One is on chromosome 21, annotated as topoisomerase IA (LmjF21.0125) with an ORF of 2453 bp. Two other type IA topoisomerases are present on chromosome 28 and 36, respectively, both of which are annotated as topoisomerase III (LmjF28.1780 and LmjF36.3200, resp.).

3.2. Identification of Topoisomerase III Genes in Leishmania donovani. One of the two topoisomerase III genes present in *L. major* geneDB is 2601 bp (LmjF28.1780) and encodes a 95 kDa predicted protein. The other topoisomerase III ORF (LmjF36.3200) is 2844 bp, and encodes a 104 kDa predicted protein. Topoisomerase III gene with 2601 bp was PCR amplified from the genomic DNA of *L. donovani*, cloned and sequenced (GeneBank accession number GQ499197). Blast analysis of the sequence confirmed the topoisomerase III lineage of the protein and henceforth referred as *LdTopIIIβ*. The alignment of *Ld*TopIIIβ with *S. cerevisiae* and *S. pombe* topoisomerase III and human topoisomerase III is shown in Figure 1. The active site tyrosine is located at the 327 position within a highly conserved GYISYPRTES sequence. The protein has 46.22% identity and 76.09% similarity with human topoisomerase IIIβ. It contains seven CXXC sequences instead of eight found in other topoisomerase IIIβ proteins. The intervening spacers are also highly conserved. Glycine (G) and arginine (R) rich clusters at the C-terminus end, which is another hallmark of topoisomerase IIIβ, are also present. It has a continuous stretch of 19 G and R residues in the C-terminus. Three-dimensional structure generated by Swiss Prot has been shown in Figure 2(a). Figure 2(b) shows the magnified view of the active site. The conserved amino acid residues are represented in ball and stick format and have been labeled. Homology comparisons of *Ld*TopIIIβ with other IA type of topoisomerases have been provided in Table 1, which strongly indicates its topoisomerase III lineage.

3.3. Localization Study of LdTopIIIβ-GFP. In silico search was carried out to determine possible localization of *Ld*TopIIIβ protein. A 0.244 probability of mitochondrial transport was predicted by Mitoprot (http://expasy.org/tools) analysis and 73.9% cytoplasmic and 17.4% nuclear distribution was revealed by PSORT II analysis (http://expasy.org/tools). To determine the precise localization of the protein, full-length *Ld*TopIIIβ (865 aa) was cloned in *Leishmania* expression vector as a C-terminal fusion protein with GFP, termed as *Ld*TopIIIβ-GFP, and the construct was transfected in *L. donovani* parasites. Localization of *Ld*TopIIIβ-GFP was viewed under fluorescence microscopy (Figure 3(a)). Nucleus and kinetoplast DNA was stained with DAPI (Figure 3(b)). Comparison of DAPI and GFP fluorescence and merged images (Figure 3(c)) revealed that *Ld*TopIIIβ protein localized both inside the nucleus and kinetoplast of the parasites. Figures 3(d) and 3(e) show cytoplasmic distribution of control GFP protein in *L. donovani* parasites.

3.4. LdTopIIIβ Suppresses the Yeast top3Δ Slow-Growth Phenotype. Mutation of the *S. cerevisiae top3* gene is known to result in several phenotypes, including a growth rate which is only 50% that of wild-type [14]. In order to assess whether the *Ld*TopIIIβ possesses functional similarity to the yeast topoisomerase III, we have used a functional complementation assay of *Ld*TopIIIβ protein to rescue *top3* mutant *S. cerevisiae* strain from slow-growing phenotype. We have cloned the *LdTOPIIIβ* gene in a shuttle vector pVT100U

```
                10         20         30         40         50         60
                |          |          |          |          |          |
Ld   MGRNVLMVAEKPSLAESIATILSNGSCSRRT---RALPVYEYTGNFMG------SPAYF
Hs   -MKTVLMVAEKPSLAQSIAKILSRGSLSSHKGLNGACSVHEYTGTFAG------QPVRF
Sc   --MKVLCVAEKNSIAKAVSQILGGGRSTSRD--SGYMYVKNYDFMFSGFPFARNGANCEV
Sp   --MRVLCVAEKNSIAKSVASILGGGHVRRRD--TRSKYVKNYDFSFN---FGGNVGSSDV
        **  ****  *:*::::  **.  *          :  *  *                 .

                70         80         90        100        110        120
                |          |          |          |          |          |
Ld   KVTSTTGHVFSCDFTSQHQNWDRTDEEQLFTAPITWKDTSG---KVTHHLEHEAQGCDTL
Hs   KMTSVCGHVMTLDFLGKYNKWDKVDPAELFSQAPTEKKEANPKLNMVKFLQVEGRGCDYI
Sc   TMTSVAGHLTGIDFSHDSHGWGKCAIQELFDAPLNEIMNNNQK-KIASNIKREARNADYL
Sp   TMTSVSGHLTEASFPSEYSSWSSVPQDVLFDAQIITSVSKNAE-VLADNIKKEARNAQYL
      .:**.  **:     .*   .   *.        **       .      :.   :: *.:..: :

               130        140        150        160        170        180
                |          |          |          |          |          |
Ld   VLWLDCDREGENICFEVMQVVRREIYNHHN----IFRAHFSAITAEEIFQAFRNLGKPNK
Hs   VLWLDCDKEGENICFEVLDAVLPVMNKAHGGEKTVFRARFSSITDTDICNAMACLGEPDH
Sc   MIWTDCDREGEYIGWEIWQEAKRGNRLIQNDQ--VYRAVFSHLERQHILNAARNPSRLDM
Sp   YIWTDCDREGEHIGVEISNVARASNPSIQ-----VIRADFNNLERSHIISAAKRPRDVSK
      :*  ***:***  *  *:  :  .    :       :  ** *.:   .*  .*    .

               190        200        210        220        230        240
                |          |          |          |          |          |
Ld   NISDAVTCRQELDLKVGVAFTRFQTKYFQGKYG---------------DLDASVISYGP
Hs   NEALSVDARQELDLRIGCAFTRFQTKYFQGKYG---------------DLDSSLISFGP
Sc   KSVHAVGTRIEIDLRAGVTFTRLLTETLRNKLRNQATMTKDGAKHRGGNKNDSQVVSYGT
Sp   NAADAVDARIELDFRLGAIFTRLQTIQLQKSFD----ILQN-----------KIISYGP
      :      :*     *  *:*::   ***:  *     ::  .         .::*:*.

               250        260        270        280        290        300
                |          |          |          |          |          |
Ld   CQTPTLGFCVQRHDEILNFKPENFWRLVP-VA-SRGGALLQFEWDRGRLFDETMARLILQ
Hs   CQTPTLGFCVERHDKIQSFKPETYWVLQAKVN-TDKDRSLLLDWDRVRVFDREIAQMFLN
Sc   CQFPTLGFVVDRFERIRNFVPEEFWYIQLVVENKDNGGTTTFQWDRGHLFDRLSVLTFYE
Sp   CQFPTLGFVVDRWQRVEDFVPETYWHLRFVD--KRQGKTIQFNWERAKVFDRLTTMIILE
      ** ***** *.*  ::  .* ** :*:    .         ::*:* ::**.  . : :

               310        320        330        340        350        360
                |          |          |          |          |          |
Ld   RITKNGK-VATVVNVSVSNDTRPRPTGLNTVDLMKIASRALGIGPHYVMSIAENLYIRGY
Hs   -MTKLEK-EAQVEATSRKEKAKQRPLALNTVEMLRVASSSLGMGPQHAMQTAERLYTQGY
Sc   TCIETAGNVAQVVDLKSKPTTKYRPLPLTTVELQKNCARYLRLNAKQSLDAAEKLYQKGF
Sp   NCLECK--TAKVVNITQKPKTKYKPLPLSTVELTKLGPKHLRISAKKTLELAENLYTNGF
       :      * *   ::  :*   *.**::  *   *   :.:  ** ** .*:

               370        380        390        400        410        420
                |          |          |          |          |          |
Ld   ISYPRTESTAYPPSFNLAGTLAQQKN-------HSMWGAYVTALLQQG------HARP
Hs   ISYPRTETTHYPENFDLKGSLRQQAN-------HPYWADTVKRLLAEG------INRP
Sc   ISYPRTETDTFPHAMDLKSLVEKQAQLDQLAAGGRTAWASYAASLLQPENTSNNNKFKFP
Sp   VSYPRTETDQFDSSMNLHAIIQKLT------G-AQEWDSYAEGLLAG------DYRPP
      :******:   :    ::*  . : :         *   . **             *

               430        440        450        460        470        480
                |          |          |          |          |          |
Ld   KAG-KDAGDHPPITPMRSAS-PGELSGDEWRIFEYITRHFIASVSPDCRLIKTKITIELG
Hs   RKG-HDAGDHPPITPMKSAT-EAELGGDAWRLYEYITRHFIATVSHDCKYLQSTISFRIG
Sc   RSGSHDDKAHPPIHPIVSLGPEANVSPVERRVYEYVARHFLACCSEDAKGQSMTLVLDWA
Sp   RKGKHNDRAHPPIHPVQMVHRSALPSQDHWKVYELITRRFLACCSDNAKGAETLVQVKME
      : *  ::  ****  *:     .  .     :::* ::*:*:* *  :.:   .   : .
```

```
                 490        500        510        520        530        540
                  |          |          |          |          |          |
Ld  GELFGISGKVVEDPGFTEIMPHARVEDDRMPTGVHKGDSFQLSDVRLQAGQTQPPSYLTE
Hs  PELFTCSGKTVLSPGFTEVMPWQSVPLEESLPTCQRGDAFPVGEVKMLEKQTNPPDYLTE
Sc  VERFSASGLVVLERNFLDVYPWARWETTKQLPRLEMNALVDIAKAEMKAGTTAPPKPMTE
Sp  EELFSKKGLLVTEKNYLEVYPYEKWESSDQLPEYRLHEEFQPHILDMMDSSTSSPSYITE
     *   *    .*    *   .  .:  ::  *           .   .     .      :      *  .*. :**

                 550        560        570        580        590        600
                  |          |          |          |          |          |
Ld  SDLIGLMEKNGIGTDASISTHVNNIVERGYCSVQAGR-----VMKPSKLGIVLIHGIKAI
Hs  AELITLMEKHGIGTDASIPVHINNICQRNYVTVESGR-----RLKPTNLGIVLVHGYYKI
Sc  SELILLMDTNGIGTDATIAEHIDKIQVRNYVRSEKVG--KETYLQPTTLGVSLVHGFEAI
Sp  PELIALMDANGIGTDATMAEHIEKVQEREYVIKRKKRGQGVTEFVPSSLGVALAKGYDEI
     .:** **: :******::. *:::: * *    .     :  *:.**: * :*    *

                 610        620        630        640        650        660
                  |          |          |          |          |          |
Ld  --DPELVLPLVRSRVEEYVTHIAEGRAQLDDVLSYSLDLFFAKFKFFKEHIDVFDALMGA
Hs  --DAELVLPTIRSAVEKQLNLIAQGKADYRQVLGHTLDVFKRKFHYFVDSIAGMDELMEV
Sc  GLEDSFAKPFQRREMEQDLKKICEGHASKTDVVKDIVEKYRKYWHKTN---ACKNTLLQV
Sp  GLEWSLTKPFLRKEMEVQLKNIENGQLNRNVLVHMILTQFRDVFHLTKQRFDCLKNSCRV
     :  .:. *   *    :*  :. * :*:. .        ::     :   :        ::           .      .

                 670        680        690        700        710        720
                  |          |          |          |          |          |
Ld  SFSAISAAGKPITRCGNCMRYLKHLDTRPQRLYCPYCEVTFALPQGGAIKPYSSFKCPID
Hs  SFSPLAATGKPLSRCGKCHRFMKYIQAKPSRLHCSHCDETYTLPQNGTIKLYKELRCPLD
Sc  YDRVKASM----------------------------------------------------
Sp  YLMSHNEPQT--------------------------------------------------

                 730        740        750        760        770        780
                  |          |          |          |          |          |
Ld  NFELVICHIEG-GKSFPICPHCYNNPPFEDMRPAIQHHHRGYGGGAAATMAPSTRHMACD
Hs  DFELVLWSSGSRGKSYPLCPYCYNHPPFRDMK-------------------KGMGCN
Sc  ------------------------------------------------------------
Sp  ------------------------------------------------------------

                 790        800        810        820        830        840
                  |          |          |          |          |          |
Ld  ECRHPTCEHSLATNYVCDCVDGSCAGSMAFVPRTTGQWKVCCNKCPMMIKLPPTAQRVYV
Hs  ECTHPSCQHSLSMLGIGQCVECESG-VLVLDPTSGPKWKVACNKCNVVAHCFENAHRVRV
Sc  ------------------------------------------------------------
Sp  ------------------------------------------------------------

                 850        860        870        880        890        900
                  |          |          |          |          |          |
Ld  TSEECPECAANCLDIMFPEGKSVLPNRKDRIVACIFCHPGLSPLCEEVRGRIGN-FRRIG
Hs  SADTCSVCEAALLDVDFNKAKSPLPGDETQHMGCVFCDPVFQELVELKHAASCHPMHRGG
Sc  ------------------------------------------------------------
Sp  ------------------------------------------------------------

                 910        920        930
                  |          |          |
Ld  GAAGGGRG-GRGGRGRGRGRGRGNREDRR-------
Hs  PGRRQGRGRGRARRPPGKPNPRRPKDKMSALAAYFV
Sc  -----------------------------------
Sp  -----------------------------------
```

Figure 1: Amino acid sequence alignment. Sequence of *Ld*TopIIIβ (Ld) was aligned with the amino acid sequences of *H. sapiens* topoisomerase IIIβ (Hs), topoisomerase III from *S. cerevisiae* (Sc) and *S. pombe* (Sp) using CLUSTAL W. The amino acids are numbered on the top of the sequences. Active site motifs and other important conserved and identical residues are depicted in red. Green and blue indicate strongly similar and weakly similar amino acids, respectively.

(a)

(b)

Figure 2: (a) Three-dimensional structure of *Ld*TopIIIβ. A ribbon structure representation of *Ld*TopIIIβ generated based on the crystal structure of *E. coli* topo isomerase III. Catalytically conserved residues are represented in ball and stick format over the ribbon structure. (b) Close up view of *Ld*TopIIIβ in which the amino acid residues that are vital for enzyme action are labeled and represented in ball and stick format. The positions of the amino acids are also mentioned.

Table 1: Amino acids homology comparisons between *Leishmania donovani* topoisomerase IIIβ (866 amino acids) and other members of typeIA topoisomerases.

Type IA topoisomerases	Identity (%)	Similarity (%)	Size (amino acids)
*Ld*TopIIIα	28.54	59.66	947
*Ld*TopIA	13.22	48.56	812
Human TopIIIα	27.14	55.47	1001
Human TopIIIβ	46.22	76.09	862
S. cerevisiae TopIII	22.96	47.33	656
S. pombe TopIII	22.56	49.32	622

to generate *LdTopIIIβ-pVT* and transformed in *top3Δ* yeast *S. cerevisiae* and Ura+ colonies were selected. Yeast cells transformed with vector pVT100U served as control in the complementation assay. The *Ld*TopIIIβ-pVT partially complemented the slow-growth of *top3Δ* yeast (Figure 4(a)). The improved growth rate was not observed in case of the vector control (Figure 4(a)). This observation suggests that *Ld*TopIIIβ can be functionally expressed in yeast and shares functional similarity with *S. cerevisiae top3* gene, which is consistent with earlier observations made with *Drosophila* and human topisomerase IIIβ proteins [19, 29]. To observe this complementation of *Ld*TopIIIβ in liquid medium a yeast growth curve analysis was carried out (Figure 4(b)). Equal amounts of the wild-type, topoisomerase 3 mutant yeast cells, topoisomerase 3 mutant yeast cells containing empty vector (pVT100U) and topoisomerase 3 mutant yeast cells containing *Ld*TopIIIβ (grown overnight at 30°C) were inoculated in fresh minimal medium and grown at 30°C. At every 2 hr interval up to 12 hrs, the growth was monitored and plotted.

3.5. Effects of Active Site Mutation of LdTopIIIβ on Complementation Ability.

Tyrosine 327 of *Ld*TopIIIβ was predicted to be the active site amino acid residue from sequence alignment analysis. In order to determine that *Ld*TopIIIβ functionally complements the *top3* mutant yeast and the growth recovery was not due to any compensatory mechanism induced by *Ld*TopIIIβ we carried out site directed mutagenesis. We have mutated the active site residue of *Ld*TopIIIβ to phenylalanine (Y327F) by site directed mutagenesis and transformed in *top3* mutant yeast. Transformed cells were grown on plate, as well as in liquid minimal media. It was observed that the active site mutant construct could not suppress the slow-growth of *top3* mutant *S. cerevisiae* (Figures 5(a) and 5(b)) confirming role of active site tyrosine 327 in functional conservation of *Ld*TopIIIβ inside mutant yeast cells.

3.6. The C-Terminal Domain of LdTopIIIβ Is Essential for In Vivo Complementation.

The *Leishmania* enzyme has a C-terminal segment of amino acids with no counterpart in yeast protein. The leishmanial protein contains Zn-binding motif at its C-terminus, which is absent in the topoisomerase III proteins of *E. coli* and yeast. The C-terminus residues of *E. coli* topoisomerase III have been previously shown to be involved in DNA binding [30]. To determine the role of the C-terminal stretch of *Ld*TopIIIβ in functional complementation, we have made a C-terminal deletion construct (*Ld*TopIIICΔ258) removing the 258 amino acids and transformed in topoisomerase III mutant yeast. The transformants were grown in plates and it was observed that the C-terminal deletion construct failed to rescue the mutant yeast from slow-growth (Figure 5(a)), suggesting essentiality of the C-terminal segment for functional complementation *in vivo*. To validate this observation in liquid medium we inoculated overnight grown cultures at 30°C in fresh minimal medium

FIGURE 3: Localization *Ld*TopIIIβ. Wild-type construct of *Ld*TopIIIβ was transfected in *L. donovani* parasites as C-terminally fused GFP proteins and viewed under fluorescence microscope (100x). Nucleus and kinetoplast DNA are visualized by DAPI staining.

and monitored their growth at 3 hr intervals. The growth curve (**Figure 5(b)**) clearly indicates that *Ld*TopIIICΔ258 could not functionally complement the slow-growing topoisomerase III mutant yeast. This indicates that the conserved C-terminal region between amino acid residues 608–866 contains important residues that are required for *in vivo* function of *Ld*TopIIICΔ258. To get a better insight into the functional characteristics of the enzyme, we next sought to obtain recombinant *Ld*TopIIIβ protein *in vitro*.

3.7. In Vitro Activity of Recombinant LdTopIII Protein. *Ld*TopIIIβ was cloned in bacterial expression vector pET-16b and overexpressed in BL21 (DE3)-pLysS strain and induced with IPTG. But the overexpressed protein went to inclusion body and were found in the pellet as insoluble protein which could not be recovered in the soluble fraction in active state. However, to test the activity of the recombinant protein, we have used *in vitro* transcription-translation kit, which is specially designed for *in vitro* transcription and translation of target DNA to protein in a single reaction. The crude lysate containing the newly synthesized proteins were used for DNA relaxation assay. **Figure 6(a)** shows DNA relaxation by increasing amount of recombinant *Ld*TopIIIβ (lanes 2–8). Lane 1 is the DNA control. The results clearly show that the recombinant protein containing lysates were able to relax the negatively supercoiled DNA. To test that the activity was not coming from the lysate itself, we have carried out DNA relaxation activity with the empty vector containing lysate which contained insignificant amount of activity, shown in **Figure 6(b)** (lane 3). Lane 2 shows DNA relaxation activity by recombinant *Ld*TopIIIβ.

4. Discussion

The type IA topoisomerases are among the most conserved proteins in nature, and their presence in all organisms is supported by extensive biochemical and genomic sequence data [2, 4]. This universal presence suggests that the type IA DNA topoisomerases play an indispensable role in one or more fundamental processes involving DNA, plausibly in the removal of double Holliday junctions [2]. Topoisomerases IIIα and IIIβ of kinetoplastid parasites seem to be orthologues of same kind of enzymes in other eukaryotes, notable for branching early within their respective groups. In the present study, for the first time we have identified functionally active DNA topoisomerase IIIβ from *L. donovani*. Blast sequence alignments suggested topoisomerase IIIβ from *Leishmania* has high homology with human and drosophila topoisomerase IIIβ. It shares many features, which are typical for other topoisomerase IIIβ proteins including the CXXC type of motifs and a long stretch of G and R residues at its C-terminus. GFP-fused *Ld*TopIIIβ localized both inside the nucleus and the kinetoplast of *L. donovani* parasites indicating the involvement of *Ld*TopIIIβ in DNA processing inside both the parasite organelle. Our results show for the first time the presence of an IA type of topoisomerase in the nucleus, as well as in the kinetoplast of *Leishmania* parasites. Previously, a IA type of topoisomerase from bacterial origin has been reported to be mitochondrial in *T. brucei* [24].

*Ld*TopIIIβ could suppress the slow-growth phenotype of the mutant yeast indicating the functional conservation of topoisomerase III activity. The result is consistent with the

(a)

(b)

FIGURE 4: Functional complementation of LdTopIIIβ. (a) *S. cerevisiae top3Δ* strain was transformed with a vector pVT100U and the vector carrying wild-type LdTopIIIβ. Transformed cells were streaked on solid synthetic minimal media and incubated at 28°C. Ten-fold serial dilutions of exponentially growing wild-type strain, *top3Δ* strain, *top3Δ* strain harboring an empty vector, or *top3Δ* strain harboring plasmid encoded LdTopIIIβ, as indicated on the right, grown on the plate. (b) Growth rate of the above-described strains were measured in the liquid synthetic medium and OD_{600} was plotted against time. Results represent the means ± standard errors of three independent experiments.

(a)

(b)

FIGURE 5: Complementation assay with mutant LdTopIIIβ. (a) Topoisomerase III mutant yeast strain was transformed with the plasmid containing wild-type (c), active site mutant (d) and C-terminal deletion construct (e) of LdTopIIIβ, separately. Transformed cells were streaked on solid synthetic minimal media and incubated at 30°C. (b) Complementation assay as described above carried out in liquid synthetic medium and OD_{600} plotted against time. Results represent the means ± standard errors of three independent experiments.

earlier observations made with human and *Drosophila* topoisomerase IIIβ enzymes. The C-terminal deletion construct of LdTopIIIβ lacking its Zn binding domain was unable to rescue the topoisomerase III mutant yeast from slow-growing phenotype revealing that the C-terminal 258 amino acids were indispensable for functional complementation of LdTopIIIβ *in vivo*. Previous report reveals the requirement of the C-terminus region of bacterial topoisomerase III in substrate specificity [30]. It is possible that C-terminal end of the leishmanial topoisomerase IIIβ protein is essential for DNA binding which requires further investigations. Site directed mutagenesis study revealed that tyrosine at 327 position within the conserved amino acid stretch is the active site tyrosine of LdTopIIIβ and when this tyrosine is mutated to phenylalanine, the protein failed to

complement the slow-growing mutant yeasts. The result indicates towards involvement of the functionally active LdTopIIIβ in rescue of the mutant yeast from slow-growth. Our attempts to purify recombinant LdTopIIIβ enzymes in active state from bacteria were unsuccessful as the proteins consistently went to inclusion body. But we were able to study, for the first time, the *in vitro* DNA relaxation activity the recombinant topoisomerase III protein from the kinetoplastid parasite *Leishmania*, when synthesized using cell free *in vitro* transcription-translation kit. Altogether, this is the first report of functionally active topoisomerase IIIβ protein from unicellular kinetoplastid parasite *Leishmania*.

The biological functions of eukaryotic topoisomerse III proteins are intriguing. Important nonoverlapping function

(a)

(b)

FIGURE 6: DNA relaxation assay by recombinant *Ld*TopIIIβ. (a) Negatively super coiled DNA was incubated with 1, 2, 3, 4, 5, 7 and 10 μL of recombinant *Ld*TopIIIβ containing lysate for 30 min (lanes 2–8). Lane 1 is the DNA control. (b) DNA relaxation assay carried out with recombinant *Ld*TopIIIβ (lane 2), and empty vector containing lysate (lane 3). Lane 1 is the DNA control.

of the two isozymes of topoimerse III has been revealed by previous studies. The mouse-knockout experiments suggests, the α form is essential for embryonic development, whereas the β form is critical for life span [20, 21]. Genetic experiments in yeast have demonstrated that *TOP3* plays a role in suppressing mitotic recombination and in resolving recombined homologous chromosomes during meiosis I [14, 31]. Preferential cleavage of plasmid-based R- and D-loops, has been reported by *Drosophila* topoisomerase IIIβ [32]. Furthermore, the combined action of either yeast or bacterial topoimerse III and the DNA helicase RecQ can promote the formation of DNA catenanes [33]. The unwinding action of a RecQ type helicase appears to generate a DNA structure that can be recognized by a topoisomerase III. RecQ helicases are also conserved in kinetoplastide parasites. The only report of functionally significant topoisomerase IIIα from kinetoplastide parasite came very recently, which describes that topoimerse IIIα from *Trypanosoma brucei* influences antigenic variation by monitoring expression-site-associated *VSG* switching [25]. Existence of functionally active topoisomerase III protein in *Leishmania* indicates towards its role in DNA metabolism in the parasites, which requires further studies and might emerge as a new therapeutic target that can be exploited against the deadly parasites.

Funding

References

[1] Y. H. Hsiang, R. Hertzberg, S. Hecht, and L. F. Liu, "Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I," *Journal of Biological Chemistry*, vol. 260, no. 27, pp. 14873–14878, 1985.

[2] J. C. Wang, "Cellular roles of DNA topoisomerases: a molecular perspective," *Nature Reviews Molecular Cell Biology*, vol. 3, no. 6, pp. 430–440, 2002.

[3] J. C. Wang, "DNA topoisomerases," *Annual Review of Biochemistry*, vol. 65, pp. 635–692, 1996.

[4] J. J. Champoux, "DNA topoisomerases: structure, function, and mechanism," *Annual Review of Biochemistry*, vol. 70, pp. 369–413, 2001.

[5] J. J. Champoux and R. Dulbecco, "An activity from mammalian cells that untwists superhelical DNA–a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay)," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 69, no. 1, pp. 143–146, 1972.

[6] R. A. Kim and J. C. Wang, "Identification of the yeast TOP_3 gene product as a single strand-specific DNA topoisomerase," *Journal of Biological Chemistry*, vol. 267, no. 24, pp. 17178–17185, 1992.

[7] Y. C. Tse-Dinh and J. C. Wang, "Complete nucleotide sequence of the topA gene encoding *Escherichia coli* DNA topoisomerase I," *Journal of Molecular Biology*, vol. 191, no. 3, pp. 321–331, 1986.

[8] R. J. DiGate and K. J. Marians, "Identification of a potent decatenating enzyme from *Escherichia coli*," *Journal of Biological Chemistry*, vol. 263, no. 26, pp. 13366–13373, 1988.

[9] R. J. DiGate and K. J. Marians, "Molecular cloning and DNA sequence analysis of *Escherichia coli* topB, the gene encoding topoisomerase III," *Journal of Biological Chemistry*, vol. 264, no. 30, pp. 17924–17930, 1989.

[10] M. Pastorcic, Ph.D. thesis, University of Chicago, 1982.

[11] K. S. Srivenugopal, D. Lockshon, and D. R. Morris, "*Escherichia coli* DNA topoisomerase III: purification and characterization of a new type I enzyme," *Biochemistry*, vol. 23, no. 9, pp. 1899–1906, 1984.

[12] A. Goodwin, S. W. Wang, T. Toda, C. Norbury, and I. D. Hickson, "Topoisomerase III is essential for accurate nuclear division in *Schizosaccharomyces pombe*," *Nucleic Acids Research*, vol. 27, no. 20, pp. 4050–4058, 1999.

[13] M. Oh, I. S. Choi, and S. D. Park, "Topoisomerase III is required for accurate DNA replication and chromosome segregation in *Schizosaccharomyces pombe*," *Nucleic Acids Research*, vol. 30, no. 18, pp. 4022–4031, 2002.

[14] J. W. Wallis, G. Chrebet, G. Brodsky, M. Rolfe, and R. Rothstein, "A hyper-recombination mutation in *S. cerevisiae* identifies a novel eukaryotic topoisomerase," *Cell*, vol. 58, no. 2, pp. 409–419, 1989.

[15] R. K. Chakraverty, J. M. Kearsey, T. J. Oakley et al., "Topoisomerase III acts upstream of Rad53p in the S-phase DNA damage checkpoint," *Molecular and Cellular Biology*, vol. 21, no. 21, pp. 7150–7162, 2001.

[16] R. Hanai, P. R. Caron, and J. C. Wang, "Human TOP₃: a single-copy gene encoding DNA topoisomerase III," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 8, pp. 3653–3657, 1996.

[17] T. Seki, M. Seki, R. Onodera, T. Katada, and T. Enomoto, "Cloning of cDNA encoding a novel mouse DNA topoisomerase III (topo IIIβ) possessing negatively supercoiled DNA relaxing activity, whose message is highly expressed in the testis," *Journal of Biological Chemistry*, vol. 273, no. 44, pp. 28553–28556, 1998.

[18] H. Goulaouic, T. Roulon, O. Flamand, L. Grondard, F. Lavelle, and J. F. Riou, "Purification and characterization of human DNA topoisomerase IIIα," *Nucleic Acids Research*, vol. 27, no. 12, pp. 2443–2450, 1999.

[19] T. M. Wilson, A. D. Chen, and T. S. Hsieh, "Cloning and characterization of Drosophila topoisomerase IIIβ. Relaxation of hypernegatively supercoiled DNA," *Journal of Biological Chemistry*, vol. 275, no. 3, pp. 1533–1540, 2000.

[20] W. Li and J. C. Wang, "Mammalian DNA topoisomerase IIIα is essential in early embryogenesis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 3, pp. 1010–1013, 1998.

[21] K. Y. Kwan and J. C. Wang, "Mice lacking DNA topoisomerase IIIβ develop to maturity but show a reduced mean lifespan," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 10, pp. 5717–5721, 2001.

[22] K. Y. Kwan, P. B. Moens, and J. C. Wang, "Infertility and aneuploidy in mice lacking a type IA DNA topoisomerase IIIβ," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 5, pp. 2526–2531, 2003.

[23] B. B. Das, T. Sengupta, A. Ganguly, and H. K. Majumder, "Topoisomerases of kinetoplastid parasites: why so fascinating?" *Molecular Microbiology*, vol. 62, no. 4, pp. 917–927, 2006.

[24] J. R. Scocca and T. A. Shapiro, "A mitochondrial topoisomerase IA essential for late theta structure resolution in African trypanosomes," *Molecular Microbiology*, vol. 67, no. 4, pp. 820–829, 2008.

[25] H.-S. Kim and G. A. M. Cross, "TOPO3α inlfluences antigenic variation by monitoring expression-site-associated *VSG* switching in *Trypanosoma brucei*," *PLoS Pathogens*, vol. 6, no. 7, Article ID e1000992, 2010.

[26] G. M. Kapler, C. M. Coburn, and S. M. Beverley, "Stable transfection of the human parasite Leishmania major delineates a 30-kilobase region sufficient for extrachromosomal replication and expression," *Molecular and Cellular Biology*, vol. 10, no. 3, pp. 1084–1094, 1990.

[27] T. Vernet, D. Dignard, and D. Y. Thomas, "A family of yeast expression vectors containing the phage f1 intergenic region," *Gene*, vol. 52, no. 2-3, pp. 225–233, 1987.

[28] D.-C. Chen, B.-C. Yang, and T.-T. Kuo, "One-step transformation of yeast in stationary phase," *Current Genetics*, vol. 21, no. 1, pp. 83–84, 1992.

[29] S. W. Ng, Y. Liu, K. T. Hasselblatt, S. C. Mok, and R. S. Berkowitz, "A new human topoisomerase III that interacts with SGS1 protein," *Nucleic Acids Research*, vol. 27, no. 4, pp. 993–1000, 1999.

[30] H. L. Zhang and R. J. DiGate, "The carboxyl-terminal residues of *Escherichia coli* DNA topoisomerase III are involved in substrate binding," *Journal of Biological Chemistry*, vol. 269, no. 12, pp. 9052–9059, 1994.

[31] S. Gangloff, B. De Massy, A. Lane, R. Rothstein, and F. Fabre, "The essential role of yeast topoisomerase III in meiosis depends on recombination," *The EMBO Journal*, vol. 18, no. 6, pp. 1701–1711, 1999.

[32] T. Wilson-Sali and T. S. Hsieh, "Preferential cleavage of plasmid-based R-loops and D-loops by Drosophila topoisomerase IIIβ," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 12, pp. 7974–7979, 2002.

[33] F. G. Harmon, R. J. DiGate, and S. C. Kowalczykowski, "RecQ helicase and topoisomerase III comprise a novel DNA strand passage function: a conserved mechanism for control of DNA recombination," *Molecular Cell*, vol. 3, no. 5, pp. 611–620, 1999.

BioMed
Research International

Stem Cells
International

International Journal of
Peptides

Advances in
Virology

International Journal of
Genomics

International Journal of
Zoology

Journal of
Signal Transduction

Journal of
Nucleic Acids

The Scientific
World Journal

Hindawi

Submit your manuscripts at
http://www.hindawi.com

Genetics
Research International

Anatomy
Research International

International Journal of
Microbiology

Biochemistry
Research International

Advances in
Bioinformatics

Archaea

Enzyme
Research

International Journal of
Evolutionary Biology

Molecular Biology
International

Journal of
Marine Biology